BIOMAT Database Logo BIOMAT Database Logo

Foscarnet (phosphonoformate sodium) in the treatment of recurrent male genital herpes. 1986

K B Lim, and S Doraisingham, and T Thirumoorthy, and C T Lee, and A E Ling, and T Tan

Foscarnet 0.3% cream was compared with placebo in a randomised double-blind study. The objective was to investigate the therapeutic efficacy and safety in men with recurrent genital herpes simplex virus (HSV) infections. A total of 51 patients were selected, of which 49 (25 treated with foscarnet) were valid for efficacy analysis. Different variables were analysed including the time to healing, alleviation of symptoms, side effects and the results of viral cultures. The median time to healing was 4 days in foscarnet treated patients compared to 5 days in placebo controls. The difference was not statistically significant (p = 0.22). However, foscarnet alleviated the severity of pain and also significantly reduced the median time to abolition pain to 3 days from 6.6 days in placebo treated patients (p = 0.0028). An antiviral effect of foscarnet was evident. The percentage of positive viral cultures found after starting treatment was 15% in the foscarnet-treated group compared to 44% in the placebo-treated group (p = 0.01). Treatment with foscarnet cream was not associated with any significant side effects.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009943 Organophosphorus Compounds Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS. Organophosphorus Compound,Organopyrophosphorus Compound,Organopyrophosphorus Compounds,Compound, Organophosphorus,Compound, Organopyrophosphorus,Compounds, Organophosphorus,Compounds, Organopyrophosphorus
D010746 Phosphonoacetic Acid A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent. Phosphonoacetate,Disodium Phosphonoacetate,Fosfonet Sodium,Phosphonacetic Acid,Phosphonoacetate, Disodium
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006558 Herpes Genitalis Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females. Genital Herpes,Herpes Simplex, Genital,Herpes Simplex Virus Genital Infection,Genital Herpes Simplex,Herpes, Genital
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations

Related Publications

K B Lim, and S Doraisingham, and T Thirumoorthy, and C T Lee, and A E Ling, and T Tan
Topical treatment of recurrent genital herpes infections with foscarnet.
January 1985, Scandinavian journal of infectious diseases,
K B Lim, and S Doraisingham, and T Thirumoorthy, and C T Lee, and A E Ling, and T Tan
Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study.
August 1986, Genitourinary medicine,
K B Lim, and S Doraisingham, and T Thirumoorthy, and C T Lee, and A E Ling, and T Tan
Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
January 1989, Pharmacology & therapeutics,
K B Lim, and S Doraisingham, and T Thirumoorthy, and C T Lee, and A E Ling, and T Tan
Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
January 1982, Pharmacology & therapeutics,
K B Lim, and S Doraisingham, and T Thirumoorthy, and C T Lee, and A E Ling, and T Tan
[Treatment of recurrent genital herpes].
January 1952, Revista medica del Hospital Espanol,
K B Lim, and S Doraisingham, and T Thirumoorthy, and C T Lee, and A E Ling, and T Tan
Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet).
March 1988, The Journal of infectious diseases,
K B Lim, and S Doraisingham, and T Thirumoorthy, and C T Lee, and A E Ling, and T Tan
Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial.
February 1987, The Journal of infectious diseases,
K B Lim, and S Doraisingham, and T Thirumoorthy, and C T Lee, and A E Ling, and T Tan
Treatment to prevent recurrent genital herpes.
February 2008, Current opinion in infectious diseases,
K B Lim, and S Doraisingham, and T Thirumoorthy, and C T Lee, and A E Ling, and T Tan
Psychosocial treatment for recurrent genital herpes.
February 1988, Journal of consulting and clinical psychology,
K B Lim, and S Doraisingham, and T Thirumoorthy, and C T Lee, and A E Ling, and T Tan
Herpes simplex virus glycoprotein treatment of recurrent genital herpes.
January 1988, The Journal of infectious diseases,
Copied contents to your clipboard!